Original Data

Insulinotropic and Anti-Inflammatory Effects of Rosiglitazone in Experimental Autoimmune Diabetes

Wageh M. Awara¹, Alaa E. El-Sisi¹, Mohamed El-Refaei², Mona M. El-Naa¹, Karima El-Desoky³

Keywords: autoimmune diabetes, thiazolidinedione, rosiglitazone, insulitis, PPAR-gamma, cytokines, nitric oxide, multiple low doses of streptozotocin

Abstract

Cytokines and nitric oxide (NO) are involved in the pathogenesis of autoimmune diabetes mellitus (DM). Rosiglitazone is an insulin-sensitizing drug that is a ligand for the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-γ). The anti-inflammatory and immunomodulating properties of PPAR-γ have been documented. The aim of this study is to investigate the effectiveness of rosiglitazone in autoimmune DM and to clarify the possible mechanism(s) involved. Autoimmune DM was induced in adult male Balb/c mice by co-administration of cyclosporin A and multiple low doses of streptozotocin. Diabetic mice were treated daily with rosiglitazone (7 mg/kg, p.o.) for 21 days. Blood glucose level (BGL), serum insulin level and pancreatic levels of tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and NO were measured. Histopathological examination and immunohistochemical determination of CD4 and CD8 T lymphocytes in the pancreatic islets were performed. In addition, analysis of pancreatic protein expression was carried out. The results showed that rosiglitazone treatment resulted in a significant decrease in the BGL and the pancreatic levels of TNF-α, IFN-γ and NO compared to diabetic mice. The serum insulin level was significantly increased after rosiglitazone treatment compared to diabetic mice. The destroyed pancreatic islets were regenerated and became free from both CD4 and CD8 T cells after treatment. Furthermore, many changes in pancreatic protein expression were observed. These results suggest that rosiglitazone has a beneficial effect in the treatment of autoimmune diabetes, an effect that seemed to be a secondary consequence of its anti-inflammatory and immunomodulating properties and might be reflected at the level of protein expression.

Fulltext: HTML , PDF (540KB)

This article has been cited by other articles:

	Differential Transcriptional Expression of PPARalpha, PPARgamma1, and PPARgamma2 in the Peritoneal Macrophages and T-cell Subsets of Non-obese Diabetic Mice Yaacob NS, Kaderi MA, Norazmi MN J Clin Immunol 2009. 29(5):595-602
	Rosiglitazone Modulates Insulin-Induced Plasma Membrane Area Changes in Single 3T3-L1 Adipocytes Velebit J, Kovacic PB, Prebil M, Chowdhury HH, Grilc S, Kreft M, Jensen J, Isenovic ER, Zorec R J Membr Biol 2008. 223(3):141-149
	Interaction among abnormal fatty acid oxidation, endothelial function disorder, and oxidative stress in the onset of severe preeclampsia Wang JL, Yang Z, Wang R, Zhu JM Zhonghua Yi Xue Za Zhi (National Medical Journal of China) 2008. 88(21):1471-1475
	Transcription factors FoxO3 a expression on adipose tissue of KKay diabetic mice and the effects of treatment with rosiglitazone and metformin Li YX, Zeng JB, Sun Q, Wang H Basic and Clinical Medicine 2008. 28(3):260-263
	Modulatory Effects of 6-Carboxymethylthiopurine on Activated Murine Macrophages De Paula ML, Braga FG, Coimbra ES, Carmo AM, Teixeira HC, Da Silva AD, Souza MA, Ferreira AP Chem Biol Drug Des 2008. 71(6):563-567